JP2023519254A5 - - Google Patents
Info
- Publication number
- JP2023519254A5 JP2023519254A5 JP2022557776A JP2022557776A JP2023519254A5 JP 2023519254 A5 JP2023519254 A5 JP 2023519254A5 JP 2022557776 A JP2022557776 A JP 2022557776A JP 2022557776 A JP2022557776 A JP 2022557776A JP 2023519254 A5 JP2023519254 A5 JP 2023519254A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- approximately
- seq
- amino acids
- monoclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062993570P | 2020-03-23 | 2020-03-23 | |
| US62/993,570 | 2020-03-23 | ||
| US202063041992P | 2020-06-21 | 2020-06-21 | |
| US63/041,992 | 2020-06-21 | ||
| US202163157618P | 2021-03-05 | 2021-03-05 | |
| US63/157,618 | 2021-03-05 | ||
| PCT/US2021/023430 WO2021194942A1 (en) | 2020-03-23 | 2021-03-22 | Anti-ccr8 antibodies for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023519254A JP2023519254A (ja) | 2023-05-10 |
| JP2023519254A5 true JP2023519254A5 (enExample) | 2024-06-26 |
| JP7855519B2 JP7855519B2 (ja) | 2026-05-08 |
Family
ID=75478295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022557776A Active JP7855519B2 (ja) | 2020-03-23 | 2021-03-22 | がんを処置するための抗ｃｃｒ８抗体 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230119066A1 (enExample) |
| EP (1) | EP4126950A1 (enExample) |
| JP (1) | JP7855519B2 (enExample) |
| KR (1) | KR20220157446A (enExample) |
| CN (1) | CN115768792A (enExample) |
| AU (1) | AU2021244200A1 (enExample) |
| BR (1) | BR112022018636A2 (enExample) |
| CA (1) | CA3172697A1 (enExample) |
| CL (2) | CL2022002555A1 (enExample) |
| CO (1) | CO2022013599A2 (enExample) |
| IL (1) | IL296673A (enExample) |
| MX (1) | MX2022011701A (enExample) |
| PE (1) | PE20230821A1 (enExample) |
| TW (1) | TW202202521A (enExample) |
| WO (1) | WO2021194942A1 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117964757A (zh) | 2020-02-14 | 2024-05-03 | 吉利德科学公司 | 与ccr8结合的抗体和融合蛋白及其用途 |
| TW202216771A (zh) | 2020-06-26 | 2022-05-01 | 德商拜耳廠股份有限公司 | 用於治療應用之ccr8抗體 |
| CA3198647A1 (en) | 2020-10-16 | 2022-04-21 | LaNova Medicines Limited | Anti-ccr8 monoclonal antibodies and uses thereof |
| JPWO2022211046A1 (enExample) | 2021-03-31 | 2022-10-06 | ||
| IL308808A (en) | 2021-06-04 | 2024-01-01 | Amgen Inc | Antibodies against CCR8 and their uses |
| EP4359442A4 (en) * | 2021-06-25 | 2025-10-15 | Nanjing Immunophage Biotech Co Ltd | ANTI-CCR8 ANTIBODIES AND THEIR USES |
| FI4214240T3 (fi) | 2021-07-27 | 2024-11-14 | Abbvie Inc | Ccr8-vasta-aineita |
| JP2024541680A (ja) * | 2021-12-02 | 2024-11-08 | ザイ ラボ （シャンハイ） カンパニー、リミテッド． | Ｃｃｒ８抗原結合ユニット及びその使用 |
| CN119930823A (zh) * | 2021-12-23 | 2025-05-06 | 乐普创一生物科技（上海）有限公司 | 抗ccr8抗体及其应用 |
| US20230279130A1 (en) * | 2022-01-14 | 2023-09-07 | Qilu Puget Sound Biotherapeutics Corporation | Anti-ccr8 antibodies |
| TW202400648A (zh) * | 2022-04-29 | 2024-01-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗ｃｃｒ８抗體及其用途 |
| US20260028409A1 (en) | 2022-05-24 | 2026-01-29 | Bristol-Myers Squibb Company | Antibodies that bind to human ccr8 |
| WO2023240135A2 (en) | 2022-06-07 | 2023-12-14 | Actinium Pharmaceuticals, Inc. | Bifunctional chelators and conjugates |
| CN115058387B (zh) * | 2022-06-11 | 2023-12-01 | 重庆医科大学 | 一种人胚胎干细胞与前列腺癌细胞共培养制备抗前列腺癌药物的方法 |
| WO2024026400A2 (en) * | 2022-07-27 | 2024-02-01 | Varian Medical Systems, Inc. | Therapeutic combinations of titr effectors with radiation therapy |
| AU2023319869A1 (en) * | 2022-08-04 | 2025-02-20 | Beone Medicines I Gmbh | Anti-ccr8 antibodies and methods of use |
| EP4573126A2 (en) * | 2022-08-19 | 2025-06-25 | Fibrogen, Inc. | Anti-ccr8 antibodies and uses thereof |
| JP2025530159A (ja) | 2022-09-09 | 2025-09-11 | バイエル・アクチエンゲゼルシヤフト | Ｃｃｒ８抗体の医学的使用および投与スケジュール |
| WO2024062076A1 (en) | 2022-09-21 | 2024-03-28 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| WO2024062072A2 (en) | 2022-09-21 | 2024-03-28 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| WO2024062019A1 (en) | 2022-09-21 | 2024-03-28 | Synabs | Anti-ccr8 antibodies and uses thereof |
| EP4590705A1 (en) | 2022-09-21 | 2025-07-30 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| AU2023356218A1 (en) * | 2022-10-07 | 2025-04-24 | Genentech, Inc. | Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies |
| KR20250091252A (ko) * | 2022-10-28 | 2025-06-20 | 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 | 항-ccr8 항체 및 이의 용도 |
| KR20250130296A (ko) | 2022-11-22 | 2025-09-01 | 상하이 홍쳉 바이오파머수티컬 코., 엘티디. | 항-ccr8 항체 및 이의 용도 |
| CN118324910A (zh) * | 2023-01-10 | 2024-07-12 | 北京天诺健成医药科技有限公司 | Ccr8抗体的应用 |
| AR131785A1 (es) | 2023-02-06 | 2025-04-30 | Bayer Ag | Combinaciones de inhibidores de dgk (diacilglicerol quinasa) |
| WO2024248037A1 (ja) | 2023-05-30 | 2024-12-05 | 塩野義製薬株式会社 | Ｃｃｒ８を抗原として認識する二重特異性抗体 |
| AU2024305430A1 (en) * | 2023-06-12 | 2026-01-22 | Nanjing Probio Biotech Co., Ltd. | Antibody binding to human ccr8 and the use thereof |
| EP4590714A1 (en) | 2023-09-21 | 2025-07-30 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| WO2025061994A1 (en) | 2023-09-21 | 2025-03-27 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| AU2024354737A1 (en) | 2023-10-06 | 2026-04-16 | Amgen Inc. | Combination therapy for cancer treatment |
| WO2025082429A1 (zh) * | 2023-10-17 | 2025-04-24 | 普米斯生物技术(珠海)有限公司 | 针对ccr8和ctla4的双特异性抗体 |
| CN117186202B (zh) * | 2023-11-08 | 2024-02-02 | 北京大学第三医院（北京大学第三临床医学院） | 一种新细胞因子csbf及其在干眼治疗中的应用 |
| TW202540200A (zh) | 2023-12-01 | 2025-10-16 | 美商基利科學股份有限公司 | 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途 |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| CN119798438B (zh) * | 2023-12-29 | 2025-11-18 | 广东东阳光药业股份有限公司 | 一种抗ccr8单克隆抗体及其应用 |
| WO2025146065A1 (en) * | 2024-01-05 | 2025-07-10 | LaNova Medicines Limited | Clinical regimens of anti-ccr8 antibodies |
| WO2025186043A1 (en) | 2024-03-06 | 2025-09-12 | Bayer Aktiengesellschaft | Pharmaceutical formulation for anti-ccr8 antibodies |
| WO2025191147A1 (en) | 2024-03-14 | 2025-09-18 | Synabs | Anti-ccr8 antibodies and uses thereof |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20260056209A1 (en) | 2024-06-14 | 2026-02-26 | Gilead Sciences, Inc. | Anti-ccr8 antibodies and uses thereof |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1176195E (pt) | 1999-04-09 | 2013-07-18 | Kyowa Hakko Kirin Co Ltd | Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico |
| PT1210428E (pt) | 1999-08-23 | 2015-07-21 | Genetics Inst Llc | Pd-1, um recetor para b7-4 e suas utilizações |
| US20040110704A1 (en) | 2002-04-09 | 2004-06-10 | Kyowa Hakko Kogyo Co., Ltd. | Cells of which genome is modified |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| US7767429B2 (en) | 2003-03-05 | 2010-08-03 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| CA2612241C (en) | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| WO2007044756A2 (en) * | 2005-10-11 | 2007-04-19 | Icos Corporation | Monoclonal antibodies recognizing human ccr8 |
| KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| AU2014201371A1 (en) * | 2007-10-31 | 2014-04-03 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| EP4209510B1 (en) | 2008-12-09 | 2024-01-31 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| NO2504364T3 (enExample) | 2009-11-24 | 2018-01-06 | ||
| SI2699264T1 (en) | 2011-04-20 | 2018-08-31 | Medimmune Llc | Antibodies and other molecules that bind b7-h1 and pd-1 |
| US9624298B2 (en) | 2011-11-28 | 2017-04-18 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
| AU2013263076B2 (en) | 2012-05-15 | 2017-08-31 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| AU2013267161A1 (en) | 2012-05-31 | 2014-11-20 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
| CA2881765C (en) * | 2012-09-19 | 2024-02-13 | Innate Pharma | Kir3dl2 binding agents |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| US9676853B2 (en) | 2013-05-31 | 2017-06-13 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-1 |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| LT3702373T (lt) | 2013-09-13 | 2022-11-10 | Beigene Switzerland Gmbh | Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai |
| HUE046249T2 (hu) | 2013-12-12 | 2020-02-28 | Shanghai hengrui pharmaceutical co ltd | PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| CA2935423C (en) | 2014-01-24 | 2023-11-07 | Dana-Farber Cancer Institute, Inc. | Antibody molecules to pd-1 and uses thereof |
| AU2015247358B2 (en) * | 2014-04-18 | 2020-02-27 | The Research Foundation For The State University Of New York | Humanized anti-TF-antigen antibodies |
| US10087259B1 (en) | 2014-04-28 | 2018-10-02 | Memorial Sloan Kettering Cancer Center | Depleting tumor-specific tregs |
| DK3237446T3 (en) | 2014-12-22 | 2021-07-26 | Pd 1 Acquisition Group Llc | Anti-PD-1-antistoffer |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| EP3307777A4 (en) | 2015-06-11 | 2019-02-13 | Wuxi Biologics (Shanghai) Co. Ltd. | NOVEL ANTI-PD-L1 ANTIBODIES |
| WO2017020291A1 (en) | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| WO2017024515A1 (en) | 2015-08-11 | 2017-02-16 | Wuxi Biologics (Cayman) Inc. | Novel anti-pd-1 antibodies |
| MX392711B (es) | 2015-08-11 | 2025-03-24 | Wuxi Biologics Ireland Ltd | Anticuerpos anti-pd-1 novedosos. |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| EP3344656A1 (en) | 2015-09-01 | 2018-07-11 | Agenus Inc. | Anti-pd-1 antibodies and methods of use thereof |
| JP6955507B2 (ja) | 2015-12-14 | 2021-10-27 | マクロジェニクス，インコーポレーテッド | Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法 |
| US11459397B2 (en) * | 2016-01-08 | 2022-10-04 | Meditope Biosciences Inc. | Self-crosslinking antibodies |
| MX2018007295A (es) | 2016-01-11 | 2019-03-28 | Armo Biosciences Inc | Interleucina 10 en la produccion de linfocitos t cd8+especificos para el antigeno y metodos de uso de estos. |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| WO2018112033A1 (en) | 2016-12-13 | 2018-06-21 | President And Fellows Of Harvard College | Methods and compositions for targeting tumor-infiltrating tregs |
| ES2863412T3 (es) * | 2017-03-29 | 2021-10-11 | Shionogi & Co | Composición farmacéutica para el tratamiento del cáncer |
| WO2019157098A1 (en) | 2018-02-06 | 2019-08-15 | Advaxis, Inc. | Compositions comprising a recombinant listeria strain and an anti-ccr8 antibody and methods of use |
| CN110835371A (zh) * | 2018-08-19 | 2020-02-25 | 普米斯生物技术(苏州)有限公司 | 抗ccr8单克隆抗体及其应用 |
| CN110835374A (zh) * | 2018-08-19 | 2020-02-25 | 普米斯生物技术(苏州)有限公司 | 抗ccr8×ctla-4双特异性抗体及其应用 |
| KR102940634B1 (ko) | 2018-12-27 | 2026-03-17 | 시오노기세이야쿠가부시키가이샤 | 신규 항 ccr8 항체 |
| TW202216771A (zh) * | 2020-06-26 | 2022-05-01 | 德商拜耳廠股份有限公司 | 用於治療應用之ccr8抗體 |
-
2021
- 2021-03-22 CN CN202180024063.9A patent/CN115768792A/zh active Pending
- 2021-03-22 US US17/914,257 patent/US20230119066A1/en active Pending
- 2021-03-22 PE PE2022002058A patent/PE20230821A1/es unknown
- 2021-03-22 IL IL296673A patent/IL296673A/en unknown
- 2021-03-22 CA CA3172697A patent/CA3172697A1/en active Pending
- 2021-03-22 WO PCT/US2021/023430 patent/WO2021194942A1/en not_active Ceased
- 2021-03-22 EP EP21718409.2A patent/EP4126950A1/en active Pending
- 2021-03-22 JP JP2022557776A patent/JP7855519B2/ja active Active
- 2021-03-22 BR BR112022018636A patent/BR112022018636A2/pt active IP Right Grant
- 2021-03-22 AU AU2021244200A patent/AU2021244200A1/en active Pending
- 2021-03-22 MX MX2022011701A patent/MX2022011701A/es unknown
- 2021-03-22 TW TW110110284A patent/TW202202521A/zh unknown
- 2021-03-22 KR KR1020227036358A patent/KR20220157446A/ko active Pending
-
2022
- 2022-09-20 CL CL2022002555A patent/CL2022002555A1/es unknown
- 2022-09-21 CO CONC2022/0013599A patent/CO2022013599A2/es unknown
-
2025
- 2025-11-13 CL CL2025003540A patent/CL2025003540A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11718681B2 (en) | Anti-SIRP α antibodies | |
| AU2021202413B2 (en) | Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors | |
| JP7855519B2 (ja) | がんを処置するための抗ｃｃｒ８抗体 | |
| US20220098302A1 (en) | Combination of dr5 agonist and anti-pd-1 antagonist and methods of use | |
| Reichert et al. | The future of antibodies as cancer drugs | |
| TWI457124B (zh) | 包含專一性辨識ｃｄ３８之抗體及長春新鹼（ｖｉｎｃｒｉｓｔｉｎｅ）之抗腫瘤組合 | |
| JP2021520201A5 (enExample) | ||
| JP2020501531A5 (enExample) | ||
| JP2018516969A5 (enExample) | ||
| CN118987201A (zh) | 治疗癌症的抗pd-1抗体和双特异性抗cd20/抗cd3抗体组合 | |
| JP2022512642A5 (enExample) | ||
| KR20200038530A (ko) | Nkg2d, cd16 및 종양-연관 항원에 결합하는 단백질 | |
| JP2021510736A5 (enExample) | ||
| JP2022512642A (ja) | がんを治療するための抗ＭｅｒＴＫ抗体 | |
| JP2024532886A5 (enExample) | ||
| JP2023543896A5 (enExample) | ||
| JP2024054123A (ja) | 癌の治療のための配合剤 | |
| JP2023525991A5 (enExample) | ||
| JP7036471B2 (ja) | デスレセプター４及びデスレセプター５に結合する非常に強力な抗体 | |
| US20250215087A1 (en) | Combination therapy of kras inhibitor and treg depleting agent | |
| AU2019306113B2 (en) | Anti-human PD-L1 antibodies and their uses | |
| WO2020221791A1 (en) | Combination of her2 antibodies | |
| WO2023001118A1 (zh) | 抗ox40抗体在联合用药中的应用 | |
| JP2025508739A5 (enExample) | ||
| Ozaki | 13 Biologic Therapies for Multiple Myeloma and Plasma Cell Disorders |